InicioCarterasWatchlistComunidadDescubreScreener
NOT FOR DISTRIBUTION
Loading...
  • Acciones
  • /
  • Sanidad
Actualizado hace 6h
VEEV logo

Veeva Systems Inc.Informe acción NYSE:VEEV

Capitalización bursátil US$42.9b
Actualizado hace 6h
Precio de las acciones
n/a
1Y-5.5%
7D1.1%
1D-0.4%
Valor de la cartera
​
Ver

Veeva Systems Inc.

Informe acción NYSE:VEEV

Capitalización de mercado: US$42.9b

  • Resumen empresa
    • Valoración
    • Crecimiento Futuro
    • Rendimiento pasado
    • Salud Financiera
    • Dividendos
  • Dirección
  • Propiedad
  • Información adicional
  • Comunidad de acciones

Veeva Systems (VEEV) Resumen de Acciones

Veeva Systems Inc. ofrece software basado en la nube para la industria de las ciencias de la vida en Norteamérica, Europa, Asia-Pacífico, Oriente Medio, África y Latinoamérica. Saber más

Análisis fundamental de VEEV
Puntuación del snowflake
Valoración2/6
Crecimiento futuro1/6
Rendimiento pasado5/6
Salud financiera6/6
Dividendos0/6

Recompensas

Cotiza un 15.3% por debajo de nuestra estimación de su valor justo

Se prevé un crecimiento anual de los beneficios de 12.65%

Los beneficios aumentaron un 25.3% el pasado año

Análisis de riesgos

VEEV ha superado nuestros controles de riesgos.

VEEV Community Fair Values

Create Narrative

See what 275 others think this stock is worth. Follow their fair value or set your own to get alerts.

Analyst Price Targets

AN
AnalystConsensusTarget
4.9% sobrevalorado descuento intrínseco
AnalystConsensusTarget
•28d ago

Pharma Wins And New Partnerships Will Drive Cloud Momentum In Coming Quarters

1.2k
0
123
AN
AnalystHighTarget
24.6% infravalorado descuento intrínseco
AnalystHighTarget
•3h ago

Rising Life Sciences Cloud Standardization And AI Adoption Will Support Strong Long Term Upside

84
0
3
AN
AnalystLowTarget
15.9% sobrevalorado descuento intrínseco
AnalystLowTarget
•14d ago

AI And Data Expansion Will Define Future Potential While Current Risks Keep Expectations Tame

113
0
5

Top Community Narratives

VEEV logo
Veeva Systems
31.2% infravalorado descuento intrínseco

AI-Powered Veeva Systems Poised for Solid Growth Amid Regulatory Stability

View narrative
JO
John_Eric
Emerging Author
John_Eric
Updated 27 Aug
Read Narrative

Top Community Narratives

VEEV logo
Veeva Systems
31.2% infravalorado descuento intrínseco

AI-Powered Veeva Systems Poised for Solid Growth Amid Regulatory Stability

View narrative
JO
John_Eric
Emerging Author
John_Eric
Updated 27 Aug
Read Narrative

Top Analyst Narratives

AN
AnalystConsensusTarget
4.9% sobrevalorado descuento intrínseco
AnalystConsensusTarget
•28d ago

Pharma Wins And New Partnerships Will Drive Cloud Momentum In Coming Quarters

1.2k
0
123
AN
AnalystHighTarget
24.6% infravalorado descuento intrínseco
AnalystHighTarget
•3h ago

Rising Life Sciences Cloud Standardization And AI Adoption Will Support Strong Long Term Upside

84
0
3
AN
AnalystLowTarget
15.9% sobrevalorado descuento intrínseco
AnalystLowTarget
•14d ago

AI And Data Expansion Will Define Future Potential While Current Risks Keep Expectations Tame

113
0
5
View all narratives

Competidores de Veeva Systems Inc.

Doximity

Symbol: NYSE:DOCS
Market cap: US$4.6b

Waystar Holding

Symbol: NasdaqGS:WAY
Market cap: US$5.1b

GoodRx Holdings

Symbol: NasdaqGS:GDRX
Market cap: US$1.2b

HealthStream

Symbol: NasdaqGS:HSTM
Market cap: US$900.1m

Historial de precios y rendimiento

Resumen de las cotizaciones máximas, mínimas y variaciones del Veeva Systems
Precios históricos de las acciones
Precio actual de la acciónUS$263.75
Máximo en las últimas 52 semanasUS$310.50
Mínimo de 52 semanasUS$148.05
Beta0.97
Cambio en 1 mes8.65%
Variación en 3 meses72.05%
Cambio de 1 año-5.49%
Variación en 3 años29.80%
Variación en 5 años-11.70%
Variación desde la OPV609.77%

Noticias y actualizaciones recientes

User avatar
Actualización de narrativa • Sep 03

VEEV: Elevated AI Optimism Will Pressure CRM Expectations Going Forward

Analysts have lifted their fair value estimate for Veeva Systems from $165.00 to about $227.65, reflecting higher assumed revenue growth and a richer future P/E multiple, partly supported by recent price target increases tied to expected billings strength, CRM wins, and perceived insulation from AI disruption. Analyst Commentary Recent Street research on Veeva Systems highlights a generally constructive view, with several firms lifting price targets and pointing to strengths in CRM, subscription growth and the company’s positioning around AI.
Seeking Alpha • Aug 27

Veeva Systems: A Combination Of Growth, Margins, And Financial Strength

Summary Veeva Systems is rated a buy, supported by durable double-digit revenue growth, expanding profitability, and a robust, debt-light balance sheet. VEEV's recurring subscription model drives high margins—Q1 FY2027 saw 75% GAAP gross margin and 86.4% subscription gross margin, with continued product adoption fueling growth. Management raised FY2027 guidance and targets a $6 billion revenue run rate by 2030, with Q2 revenue expected to exceed guidance. Valuation risk has moderated, with VEEV now trading at 44x trailing and 38x forward earnings as the company grows into its premium multiple. Read the full article on Seeking Alpha

Recent updates

User avatar
Actualización de narrativa • Sep 03

VEEV: Elevated AI Optimism Will Pressure CRM Expectations Going Forward

Analysts have lifted their fair value estimate for Veeva Systems from $165.00 to about $227.65, reflecting higher assumed revenue growth and a richer future P/E multiple, partly supported by recent price target increases tied to expected billings strength, CRM wins, and perceived insulation from AI disruption. Analyst Commentary Recent Street research on Veeva Systems highlights a generally constructive view, with several firms lifting price targets and pointing to strengths in CRM, subscription growth and the company’s positioning around AI.
Seeking Alpha • Aug 27

Veeva Systems: A Combination Of Growth, Margins, And Financial Strength

Summary Veeva Systems is rated a buy, supported by durable double-digit revenue growth, expanding profitability, and a robust, debt-light balance sheet. VEEV's recurring subscription model drives high margins—Q1 FY2027 saw 75% GAAP gross margin and 86.4% subscription gross margin, with continued product adoption fueling growth. Management raised FY2027 guidance and targets a $6 billion revenue run rate by 2030, with Q2 revenue expected to exceed guidance. Valuation risk has moderated, with VEEV now trading at 44x trailing and 38x forward earnings as the company grows into its premium multiple. Read the full article on Seeking Alpha
User avatar
Actualización de narrativa • Aug 27

Veeva Just Had a Great Quarter. That's Exactly Why I'm Not Buying More.

Revenue beat. Earnings beat.
User avatar
Actualización de narrativa • Aug 20

VEEV: AI Demand And CRM Wins Will Support Balanced Future Returns

Veeva Systems' analyst-derived fair value estimate has moved from $245.48 to $251.43 as analysts factor in Street research pointing to steadier normalized billings growth, customer interest in AI and CRM offerings, and mixed but generally constructive views on long term demand. Analyst Commentary Recent Street views on Veeva Systems show a wide range of opinions on execution, growth durability, and how current pricing lines up with perceived fundamentals.
User avatar
Actualización de narrativa • Jul 13

VEEV: AI Disruption Fears Will Pressure Core CRM Durability

Veeva Systems' updated analyst price target has been reduced from about $232.80 to $165.00. Analysts cite slightly lower modeled revenue growth, a lower assumed future P/E multiple, and ongoing debates around AI disruption and competitive pressure in core CRM offerings, despite steady Q1 execution and continued AI product development.
User avatar
Nueva narrativa • Jul 03

AI-Powered Veeva Systems Poised for Solid Growth Amid Regulatory Stability

Investors often look for artificial intelligence winners in the obvious places: semiconductors, hyperscalers, and general-purpose software platforms. But some of the most durable AI opportunities may sit in far less glamorous places—inside the regulated workflows where a mistake is not merely inconvenient, but potentially delays a drug trial, a regulatory submission, or a therapy reaching patients.
User avatar
Actualización de narrativa • Jun 29

VEEV: AI Execution And CRM Wins Will Drive Future Upside

Veeva Systems’ analyst fair value estimate has been reset lower from about $380 to roughly $338, reflecting Street price target cuts as analysts weigh solid Q1 execution against AI disruption risk, competitive CRM questions, and a shift toward more measured profit margin and P/E assumptions. Analyst Commentary Street research on Veeva Systems presents a mixed but generally constructive picture, with many firms recalibrating price targets while still pointing to solid Q1 execution, ongoing demand in health technology, and emerging AI and CRM catalysts as key elements in their valuation work.
Artículo de análisis • Jun 20

Veeva Systems (VEEV) Stock Could Be 38% Undervalued After Fed Driven Pullback

Veeva Systems (VEEV) shares fell after the Federal Reserve held its benchmark rate and signaled a more restrictive stance, as higher Treasury yields weighed on software sector valuations, including healthcare and life sciences platforms. See our latest analysis for Veeva Systems. At around US$153.30, Veeva Systems’ recent share price weakness has been broad based, with a 1 day share price return of 1% and a year to date share price return down 30.16%, while the 1 year total shareholder return...
User avatar
Actualización de narrativa • Jun 15

VEEV: AI Execution And CRM Wins Will Support Future Multiple Reacceleration

Narrative Update The analyst price target for Veeva Systems in this framework is updated from about $263 to about $245, as analysts balance solid Q1 execution and raised guidance with AI disruption risk, CRM competition from Salesforce, and questions around the quality and mix of recent upside, particularly in services. Analyst Commentary Recent research on Veeva Systems reflects a split view, with most analysts acknowledging solid Q1 execution and raised guidance, but debating how much weight to give AI disruption risk, CRM competition, and the quality of services driven upside when thinking about valuation, execution, and long term growth.
User avatar
Actualización de narrativa • Jun 01

VEEV: AI Moat And CRM Commitments Will Support Future Multiple Reacceleration

Narrative Update The analyst price target for Veeva Systems has been trimmed by about $2 to $262.68 as analysts factor in compressed software multiples, while largely maintaining their underlying growth, margin, and P/E assumptions. Analyst Commentary Recent research on Veeva Systems clusters around strong reported execution in Q4, tempered by valuation resets tied to compressed software multiples and longer term questions around AI and CRM competition.
User avatar
Actualización de narrativa • May 11

VEEV: AI Moat And CRM Commitments Will Support Premium Multiple

Veeva Systems' updated analyst price target edges lower to about $264 from roughly $265, as analysts keep their broadly positive take on the company's recent Q4 results but adjust valuation assumptions to reflect compressed software multiples and ongoing debates around AI, R&D growth, and CRM stability. Analyst Commentary Recent research on Veeva reflects a mix of optimism about execution in Q4 and caution around valuation and longer term growth drivers.
User avatar
Actualización de narrativa • Apr 25

VEEV: AI Moat And Subscription Resilience Will Support Premium Multiple

Analysts have trimmed the Veeva Systems price target slightly, with the model fair value moving from about $270.93 to $264.46, as modestly lower assumed future P/E multiples more than offset largely unchanged growth and margin expectations. Analyst Commentary Recent Street research around Veeva Systems shows a split view, with many firms trimming price targets while still pointing to solid execution and specific areas of uncertainty that could influence the valuation over time.
User avatar
Actualización de narrativa • Apr 08

VEEV: AI And Subscription Resilience Will Support Premium Software Multiple

Analysts trimmed the blended Veeva Systems price target by aligning with sector wide software multiple compression, even as they point to strong Q4 execution, resilient subscription growth, and an emerging AI and product pipeline as key longer term supports. Analyst Commentary Recent Street research around Veeva Systems reflects a mix of optimism on execution and growth, alongside more cautious views on competitive risk, AI impact, and valuation.
User avatar
Actualización de narrativa • Mar 25

VEEV: AI Adoption In R&D Workflows Will Support Durable Premium Outlook

Analysts have adjusted their price targets on Veeva Systems into a roughly $190 to $317 range, generally trimming prior targets by tens of dollars as software valuation multiples compress, even after what they describe as solid Q4 results and broadly constructive longer term fundamentals. Analyst Commentary Recent research paints a mixed but generally constructive picture for Veeva Systems, with most firms trimming price targets while still pointing to solid execution and durable fundamentals.
User avatar
Actualización de narrativa • Mar 11

VEEV: AI Adoption And CRM Commitments Will Support Durable Premium Outlook

We are trimming our Veeva Systems fair value estimate to $270.93 from $302.60, as analysts broadly reset price targets in response to sector wide software multiple compression and slightly more measured assumptions for revenue growth, margins, and future P/E multiples, despite generally solid Q4 results and guidance. Analyst Commentary Street research on Veeva Systems has become more mixed, with many firms cutting price targets while still acknowledging solid Q4 execution and robust profitability.
User avatar
Actualización de narrativa • Feb 25

VEEV: AI Execution And CRM Stability Will Support Durable Premium Outlook

Our fair value estimate for Veeva Systems has edged down from $308.63 to $302.60. This reflects a series of reduced Street price targets as analysts weigh maturing products, competitive pressures, software sentiment, and the balance of growth opportunities against current valuation.
User avatar
Actualización de narrativa • Feb 10

VEEV: Roche Commitment And CRM Retention Will Support Durable Premium Outlook

Our analyst fair value estimate for Veeva Systems has been trimmed slightly to $308.63. This reflects a modest reset in Street price targets as analysts balance concerns about slower growth in maturing products and competitive pressure with ongoing strengths in areas like Crossix, AI adoption, and large CRM wins such as Roche.
User avatar
Nueva narrativa • Jan 28

Rising Life Sciences Cloud Standardization And AI Adoption Will Support Strong Long Term Upside

Catalysts About Veeva Systems Veeva Systems provides cloud based software, data and consulting services to life sciences companies across commercial, R&D and manufacturing functions. What are the underlying business or industry changes driving this perspective?
User avatar
Actualización de narrativa • Jan 27

VEEV: Roche Rollout And CRM Retention Will Support Durable Premium Outlook

The analyst price target embedded in our Veeva Systems model edges slightly lower to about US$310 from roughly US$311. This reflects a blend of more cautious views on growth and competitive pressure, along with offsetting positive views on durable margins, CRM customer retention, and newer areas such as Crossix and early AI traction.
User avatar
Actualización de narrativa • Jan 12

VEEV: Roche Expansion And CRM Migrations Will Support Durable Premium Outlook

Analysts have trimmed their fair value estimate for Veeva Systems by about US$1 to US$310.98, reflecting modest adjustments to discount rate and growth assumptions while still pointing to what they see as durable growth drivers such as pharma CRM migrations, broader Vault adoption and newer areas like Crossix and AI. Analyst Commentary Recent Street research on Veeva Systems reflects a mix of optimism and caution, with differing views clustering around the durability of growth in CRM and Vault, the timing of pharma migrations, and how current valuation stacks up against execution and contract wins.
User avatar
Actualización de narrativa • Dec 19

VEEV: Roche Commitment And CRM Migrations Will Likely Sustain Premium Outlook

Analysts have modestly trimmed their blended price target for Veeva Systems to about $312 from roughly $321, reflecting a slightly higher discount rate and lower implied future multiple, even as they highlight accelerating CRM migrations, including Roche's global Vault CRM rollout, and improving long term growth and margin expectations. Analyst Commentary Street research remains broadly constructive on Veeva Systems, with recent target changes reflecting a recalibration of software multiples rather than a material shift in company specific fundamentals.
Artículo de análisis • Dec 03

Veeva Systems' (NYSE:VEEV) Performance Is Even Better Than Its Earnings Suggest

Investors were underwhelmed by the solid earnings posted by Veeva Systems Inc. ( NYSE:VEEV ) recently. We have done...
User avatar
Actualización de narrativa • Nov 11

VEEV: Continued Momentum And New Commitments Will Likely Sustain Premium Outlook

Analysts have significantly raised their price targets on Veeva Systems, with recent updates moving targets as high as $380. They cite the company's strong sales growth prospects and solid momentum, driven by accelerating CRM customer commitments and new partnerships.
User avatar
Actualización de narrativa • Oct 27

Pharma Wins And New Partnerships Will Drive Cloud Momentum In Coming Quarters

Veeva Systems' analyst price target saw a significant increase, rising by more than $80 to reflect higher expectations for sales growth and ongoing customer commitments. Analysts cited the company’s strengthening position in CRM and positive momentum across key pharma relationships.
User avatar
Actualización de narrativa • Oct 13

IQVIA Resolution And Embedded AI Will Expand Digital Healthcare Cloud

Narrative Update on Veeva Systems: Analyst Price Target Revision Analysts have raised their fair value estimate for Veeva Systems to approximately $321 per share, up by nearly $4. They cited stronger than expected sales momentum, driven by new major customer commitments and continued growth in key business segments.
User avatar
Actualización de narrativa • Aug 29

Data Cloud Expansion And AI Efficiencies Will Drive Future Success

Analysts have raised their price target for Veeva Systems to $314.71, citing strong Q2 “beat and raise” results, momentum in both Commercial and R&D segments, successful Vault CRM rollouts with major pharma clients, and ongoing market share gains in life sciences CRM. Analyst Commentary Bullish analysts highlighted Veeva's strong “beat and raise” Q2 results, with both subscription and services revenues growing solidly year-over-year, driven by performance in both Commercial and R&D technology segments.
Seeking Alpha • Apr 17

Veeva Systems: Substantially Overvalued As Growth Slows

Summary Veeva Systems is overvalued, trading at frothy levels despite only ~10% growth, and facing a potential slowdown in 2025; I recommend a sell rating. The company excels in the life sciences vertical with unique solutions but its ambitious revenue targets (doubling revenue by 2030) may be tough to achieve organically. Valuation multiples are high at ~10 EV/FY26 revenue and ~30x FY26 P/E, well above a number of peers - some of which are growing even faster than Veeva. Read the full article on Seeking Alpha
Seeking Alpha • Mar 19

Veeva Systems: Staying Buy Rated As VEEV Is Executing Well

Summary I reaffirm my buy rating on Veeva Systems due to strong 4Q25 results, driven by R&D growth and positive Vault CRM adoption traction. VEEV's revenue grew 14% y/y to $721 million, beating expectations, with significant margin improvements and a strong balance sheet. Vault CRM added 20 new customers, with multiple top 20 pharma commitments expected in 2025, signaling positive transition progress. Data Cloud segment shows strong momentum, with new initiatives like Pulse expected to drive further CRM adoption and growth. Read the full article on Seeking Alpha
Seeking Alpha • Mar 07

Veeva Systems: Solid Q4 With Margin Expansion

Summary I reiterate my “Strong Buy” rating on Veeva Systems Inc. with a one-year target price of $275 per share due to strong CRM migration and margin improvement. Veeva reported 14.3% revenue growth and 28.7% adjusted operating profit growth, driven by robust CRM adoption and billing growth. Management's guidance for FY26 includes $3.04-$3.055 billion in revenue, with anticipated 12% revenue growth despite high-interest rate challenges. I foresee continued margin expansion and revenue growth recovery to 16% by FY27 for VEEV, supported by CRM migration and easing capital funding challenges. Read the full article on Seeking Alpha

Rentabilidad de los accionistas

VEEVUS Healthcare ServicesMercado US
7D1.1%4.1%0.5%
1Y-5.5%-17.5%12.0%

Rentabilidad vs. Industria: VEEV superó a la industria US Healthcare Services, que obtuvo un rendimiento del -17.5% el año pasado.

Rentabilidad vs. Mercado: VEEV obtuvo unos resultados inferiores a los del mercado US, que fueron del 12% el año pasado.

Volatilidad de los precios

Is VEEV's price volatile compared to industry and market?
VEEV volatility
VEEV Average Weekly Movement7.0%
Healthcare Services Industry Average Movement10.4%
Market Average Movement6.8%
10% most volatile stocks in US Market15.2%
10% least volatile stocks in US Market2.9%

Precio estable de las acciones: VEEV no ha tenido una volatilidad de precios significativa en los últimos 3 meses en comparación con el mercado US.

Volatilidad a lo largo del tiempo: La volatilidad semanal de VEEV (7%) se ha mantenido estable durante el año pasado.

Acerca de la empresa

FundadaEmpleadosCEOPágina web
20077,928Peter Gassnerwww.veeva.com

Veeva Systems Inc. proporciona software basado en la nube para la industria de las ciencias de la vida en Norteamérica, Europa, Asia-Pacífico, Oriente Medio, África y Latinoamérica. La empresa ofrece Veeva Commercial Cloud, que comprende Veeva Vault CRM Suite para empresas farmacéuticas y biotecnológicas; Veeva Medical, que proporciona una fuente de contenido médico a través de múltiples canales y geografías; Veeva PromoMats, una solución integral de gestión de contenidos y activos digitales; y Veeva Crossix, una plataforma de análisis para marcas farmacéuticas. También proporciona Veeva Data Cloud, como Veeva OpenData, una solución de datos de referencia de clientes; Veeva Link, que proporciona datos profundos; Veeva Compass, que incluye datos de pacientes longitudinales y desidentificados; y Veeva CRM Pulse que proporciona acceso y métricas de compromiso multicanal.

Resumen de fundamentos de Veeva Systems Inc.

¿Cómo se comparan los beneficios e ingresos de Veeva Systems con su capitalización de mercado?
Estadísticas fundamentales de VEEV
Capitalización bursátilUS$42.89b
Beneficios(TTM)US$1.01b
Ingresos (TTM)US$3.46b
42.1x
Ratio precio-beneficio (PE)
12.3x
Ratio precio-ventas (PS)

¿Está VEEV sobrevalorada?

Ver valor justo y análisis de valoración

Beneficios e Ingresos

Estadísticas clave de rentabilidad del último informe de resultados (TTM)
Cuenta de resultados (TTM) de VEEV
IngresosUS$3.46b
Coste de los ingresosUS$865.88m
Beneficio brutoUS$2.59b
Otros gastosUS$1.58b
BeneficiosUS$1.01b

Últimos beneficios comunicados

Jul 31, 2026

Próxima fecha de beneficios

n/a

Beneficios por acción (BPA)6.27
Margen bruto74.96%
Margen de beneficio neto29.34%
Ratio deuda/patrimonio0%

¿Cómo se ha desempeñado VEEV a largo plazo?

Ver rendimiento histórico y comparativa

Análisis de la empresa y estado de los datos financieros

DatosÚltima actualización (huso horario UTC)
Análisis de la empresa2026/09/17 22:07
Precio de las acciones al final del día2026/09/17 00:00
Beneficios2026/07/31
Ingresos anuales2026/01/31

Fuentes de datos

Los datos utilizados en nuestro análisis de empresas proceden de S&P Global Market Intelligence LLC. Los siguientes datos se utilizan en nuestro modelo de análisis para generar este informe. Los datos están normalizados, lo que puede introducir un retraso desde que la fuente está disponible.

PaqueteDatosMarco temporalEjemplo Fuente EE.UU. *
Finanzas de la empresa10 años
  • Cuenta de resultados
  • Estado de tesorería
  • Balance
  • Formulario SEC 10-K
  • Formulario SEC 10-Q
Estimaciones del consenso de analistas+3 años
  • Previsiones financieras
  • Objetivos de precios de los analistas
  • Informes de análisis
  • Blue Matrix
Precios de mercado30 años
  • Precios de las acciones
  • Dividendos, escisiones y acciones
  • Datos de mercado ICE
  • Formulario S-1 de la SEC
Propiedad10 años
  • Accionistas principales
  • Información privilegiada
  • Formulario SEC 4
  • Formulario SEC 13D
Gestión10 años
  • Equipo directivo
  • Consejo de Administración
  • Formulario SEC 10-K
  • Formulario SEC DEF 14A
Principales avances10 años
  • Anuncios de empresas
  • Formulario SEC 8-K

* Ejemplo para valores de EE.UU., para no EE.UU. se utilizan formularios y fuentes normativas equivalentes.

A menos que se especifique lo contrario, todos los datos financieros se basan en un periodo anual, pero se actualizan trimestralmente. Esto se conoce como datos de los últimos doce meses (TTM) o de los últimos doce meses (LTM). Más información.

Modelo de análisis y copo de nieve

Los detalles del modelo de análisis utilizado para generar este informe están disponibles en nuestra página de Github, también tenemos guías sobre cómo utilizar nuestros informes y tutoriales en Youtube.

Conozca al que diseñó y construyó el modelo de análisis Simply Wall St.

Métricas industriales y sectoriales

Simply Wall St calcula cada 6 horas nuestras métricas sectoriales y de sección. Los detalles de nuestro proceso están disponibles en Github.

Fuentes analistas

Veeva Systems Inc. está cubierta por 47 analistas. 27 de esos analistas presentaron las estimaciones de ingresos o ganancias utilizadas como datos para nuestro informe. Las estimaciones de los analistas se actualizan a lo largo del día.

AnalistaInstitución
Joseph VruwinkBaird
Saket KaliaBarclays
"Saket KaliaBarclays

Toma mejores decisiones de inversión en cualquier lugar

Escanea para descargar
Abrir AppStoreAbrir Google Play
Chrome Web Store
Level 5, 320 Pitt Street, Sydney
Financial Data provided by S&P Global Market Intelligence LLC, analysis provided by Simply Wall Street Pty Ltd. Copyright © 2026, S&P Global Market Intelligence LLC. All rights reserved.
Ver fuentes de datos
Mercados
  • US: NYSE & NASDAQ
  • UK: FTSE
  • Australia: ASX
  • India: NIFTY
  • Canada: TSX
  • South Africa: JSE
  • Japan: NIKKEI
  • South Korea: KOSPI
  • Germany: DAX
Ideas de inversión
  • Empresas infravaloradas
  • Potentes generadores de dividendos
  • Compras con información privilegiada
  • Energía nuclear
  • Vehículos autónomos
  • Inteligencia artificial
  • Criptomonedas y blockchain
  • Ciberseguridad
  • Más ideas
Comunidades de acciones
  • AstraZeneca
  • HSBC Holdings
  • Shell
  • Unilever
  • Diageo
  • Rio Tinto Group
  • RELX
  • BP
  • Barclays
Herramientas y funciones
  • Seguimiento de la cartera
  • Buscador de valores y alertas
  • Narrativas y Valores de Feria
  • Calculadora de dividendos
Noticias y descubrimientos
  • Últimas noticias de stock
  • Incidencias del mercado global
  • El Foxhole
  • Ideas de inversión
  • Narrativas de la comunidad
  • Qué hay de nuevo
Simply Wall St
  • Planes y precios
  • Publicidad
  • Quiénes somos
  • Contacte con nosotros
  • Empleos
  • Centro de ayuda
  • Aprender a invertir en bolsa
  • Programa de afiliados
  • Empresas y negocios
  • Charlie AI
Simply Wall Street Pty Ltd (ACN 600 056 611), is a Corporate Authorised Representative (Authorised Representative Number: 467183) of Sanlam Private Wealth Pty Ltd (AFSL No. 337927). Any advice contained in this website is general advice only and has been prepared without considering your objectives, financial situation or needs. You should not rely on any advice and/or information contained in this website and before making any investment decision we recommend that you consider whether it is appropriate for your situation and seek appropriate financial, taxation and legal advice. Please read our Financial Services Guide before deciding whether to obtain financial services from us.
© 2026 Simply Wall Street Pty Ltd, US Design Patent #29/544/281, Community and European Design Registration #2845206
  • Términos y condiciones de uso
  • Política de privacidad
  • Términos de IA
  • Guía de servicios financieros